Cosmo Pharmaceuticals N.V.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CMOPF research report →
About the company
Cosmo Pharmaceuticals N. V. , a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally.
- CEO
- Giovanni di Napoli
- IPO
- 2017
- Employees
- 324
- HQ
- Dublin, IE
Price Chart
- Market Cap
- $1.41B
- P/E
- -339.43
- P/S
- 12.61
- P/B
- 2.54
- EV/EBITDA
- 179.29
- Div Yield
- 2.74%
- Gross Margin
- 48.53%
- Op Margin
- -5.49%
- Net Margin
- -3.46%
- ROE
- -0.77%
- ROIC
- -0.97%
- Revenue
- $104.82M · -60.71%
- Net Income
- $-3,630,478 · -102.72%
- EPS
- $-0.23 · -102.82%
- Op Income
- $-10,479,888
- FCF YoY
- -110.11%
- 52W High
- $169.90
- 52W Low
- $64.37
- 50D MA
- $95.06
- 200D MA
- $109.71
- Beta
- 1.49
- Avg Volume
- 379
Get TickerSpark's AI analysis on CMOPF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our CMOPF coverage
Recent articles, reports, and earnings notes.
No research on CMOPF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CMOPF report →Similar companies
Peers in the same neighborhood.